Duloxetine: In stress urinary incontinence

Drugs

Volumn 64, Issue 22, 2004, Pages 2567-2573

  McCormack, Paul L ^a   Keating, Gillian M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

DULOXETINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

ANOREXIA; BLADDER SPHINCTER; CONSTIPATION; DIARRHEA; DIZZINESS; DOSE RESPONSE; FATIGUE; HEADACHE; HUMAN; INSOMNIA; NAUSEA; PELVIS FLOOR; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; SOMNOLENCE; STRESS INCONTINENCE; TREMOR; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; AREA UNDER CURVE; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; METABOLIC CLEARANCE RATE; SEROTONIN UPTAKE INHIBITORS; STRESS; THIOPHENES; URINARY INCONTINENCE;

EID: 9744277490     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200464220-00005     Document Type: Review

References (37)

1. Harrison GL, Memel DS. Urinary incontinence in women: its prevalence and its management in a health promotion clinic. Br J Gen Pract 1994 Apr; 44 (381): 149-52
2. Brown JS, Grady D, Ouslander JG, et al. Prevalence of urinary incontinence and associated risk factors in postmenopausal women: Heart & Estrogen/Progestin Replacement Study (HERS) Research Group. Obstet Gynecol 1999 Jul; 94 (1): 66-70
3. Viktrup L. Female stress and urge incontinence in family practice: insight into the lower urinary tract. Int J Clin Pract 2002; 56 (9): 694-700
4. Resnick NM, Griffiths DJ. Expanding treatment options for stress urinary incontinence in women. JAMA 2003 Jul 16; 290 (3): 395-7
5. Culligan PJ, Heit M. Urinary incontinence in women: evaluation and management. Am Fam Physician 2000 Dec 1; 62 (11): 2433-44, 2447, 2452
6. Chaliha C, Khullar V. Mixed incontinence. Urology 2004 Mar; 63 Suppl. 3A: 51-7
7. Siroky MB. Current treatment options for stress urinary incontinence. Adv Stud Med 2003; 3 (8E): S834-8
8. Ostergard DR. New approaches to the treatment of stress urinary incontinence. Adv Stud Med 2004; 4 (2A): S88-94
9. Schuessler B, Baessler K. Pharmacologic treatment of stress urinary incontinence: expectations for outcome. Urology 2003 Oct; 62 Suppl. 4A: 31-8
10. Eli Lilly and Company. FDA approves Lilly's Cymbalta® for the treatment of depression [media release]. 2004
11. European Medicines Agency. Committee for Medicinal Products for Human Use summary of opinion for Xeristar [online]. Available from URL: http://www.emea.eu.int [Accessed 2004 Oct 12]
12. European Medicines Agency. Committee for Medicinal Products for Human Use: summary of opinion for Cymbalta [on-line]. Available from URL: http://www.emea.eu.int/pdfs/human/opinion/4721604en.pdf [Accessed 2004 Oct 12]
13. Eli Lilly and Company. FDA approves antidepressant Cymbalta® for treatment of pain caused by diabetic peripheral neuropathy, which affects up to 5 million Americans [media release]. 2004
14. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993; 8 (1): 23-33
15. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002; 8 (4): 361-76
16. Thor KB. Serotonin and norepinephrine involvement in efferent pathways to the urethral rhabdosphincter: implications for treating stress urinary incontinence. Urology 2003 Oct; 62 Suppl. 4A: 3-9
17. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274 (2): 1014-24
18. Katofiasc MA, Nissen J, Audia JE, et al. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002; 71: 1227-36
19. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004 Jan; 57 (1): 54-61
20. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003 Sep; 31 (9): 1142-50
21. Granier LA, Vandenhende F, de Suray JM, et al. Safety and pharmacokinetics of duloxetine, a potential new antidepressant with serotonin and norepinephrine uptake inhibition [abstract no. P.1.043]. Eur Neuropsychopharmacol 1999 Sep; 9 Suppl. 5: S222
22. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000; 40 (2): 161-7
23. DeLong AF, Johnson JT, Oldham SW, et al. Disposition of 14C duloxetine after oral administration in man [abstract no. 4005]. FASEB J 1995 Mar 10; 9 (4 Pt II): 691
24. Skinner MH, Skerjanec A, Seger M, et al. The effect of food and bedtime administration on duloxetine pharmacokinetics [abstract no. PII-59]. Clin Pharmacol Ther 2000 Feb; 67 (2): 129
25. Ishigooka J, Nagata E, Takahashi A, et al. Simultaneous monitoring of inhibition of serotonin uptake by platelets and plasma drug concentrations following administration of duloxetine, a new antidepressant candidate, to healthy volunteers. Curr Ther Res 1997 Oct; 58 (10): 679-92
26. Eli Lilly Nederland BV. Yentreve®: summary of product characteristics [online]. Available from URL: http://www.emea.eu.int/humandocs/Humans/EPAR/ yentreve/yentreve.htm [Accessed 2004 Oct 11]
27. van Kerrebroeck P, Abrams P, Lange R, et al. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence: Duloxetine Urinary Incontinence Study Group. BJOG 2004 Mar; 111 (3): 249-57
28. Millard RJ, Moore K, Rencken R, et al. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Duloxetine UI Study Group. BJU Int 2004 Feb; 93 (3): 311-8
29. Dmochowski RR, Miklos JR, Norton PA, et al. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence: Duloxetine Urinary Incontinence Study Group. J Urol 2003 Oct; 170 (4 Pt 1): 1259-63
30. Norton PA, Zinner NR, Yalcin I, et al. Duloxetine versus placebo in the treatment of stress urinary incontinence: Duloxetine Urinary Incontinence Study Group. Am J Obstet Gynecol 2002 Jul; 187 (1): 40-8
31. Cardozo L, Drutz HP, Baygani SK, et al. Pharmacological treatment of women awaiting surgery for stress urinary incontinence: Duloxetine Severe UI Study Group. Obstet Gynecol 2004 Sep; 104 (3): 511-9
32. Ghoniem GM, Elser DM, Freeman R, et al. Controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment, and no treatment in women with stress urinary incontinence [abstract no. 1239]. J Urol 2004 Apr; 171 Suppl. 4: 326
33. Yalcin I, Versi E, Benson JT, et al. Validation of a clinical algorithm to diagnose stress urinary incontinence for large studies. J Urol 2004 Jun; 171 (6 Pt 1): 2321-5
34. Bump RC, Norton PA, Zinner NR, et al. Mixed urinary incontinence symptoms: urodynamic findings, incontinence severity, and treatment response: Duloxetine Urinary Incontinence Study Group. Obstet Gynecol 2003 Jul; 102 (1): 76-83
35. Eli Lilly and Company, Boehringer Ingelheim. Yentreve™ receives approval across the European Union for the treatment of stress urinary incontinence in women [media release]. 2004
36. Boehringer Ingelheim. Yentreve®/Ariclaim® now approved throughout the European Union for the treatment of stress urinary incontinence in women [media release]. 2004
37. Eli Lilly and Company. FDA issues approvable letter for duloxetine for stress urinary incontinence (SUI); Lilly expects regulatory update on Cymbalta later this year [media release]. 2003